Adicet Bio
ACET
101 hedge funds and large institutions have $556M invested in Adicet Bio in 2022 Q2 according to their latest regulatory filings, with 32 funds opening new positions, 35 increasing their positions, 14 reducing their positions, and 15 closing their positions.
150% more repeat investments, than reductions
Existing positions increased: 35 | Existing positions reduced: 14
113% more first-time investments, than exits
New positions opened: 32 | Existing positions closed: 15
96% more call options, than puts
Call options by funds: $2.19M | Put options by funds: $1.12M
44% more capital inflows, than outflows
Capital inflows: $139M | Capital outflows: $96.4M
16% more funds holding
Funds holding: 87 → 101 (+14)
11.98% more ownership
Funds ownership: 82.99% → 94.97% (+12%)
11% less funds holding in top 10
Funds holding in top 10: 9 → 8 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$22.2M |
| 2 |
Candriam SCA
Strassen, Luxembourg,
Luxembourg
|
+$17.6M |
| 3 |
Cormorant Asset Management
Boston,
Massachusetts
|
+$14.4M |
| 4 |
RTW Investments
New York
|
+$13.2M |
| 5 |
Cowen and Company
New York
|
+$13M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Avidity Partners Management
Dallas,
Texas
|
-$62.3M |
| 2 |
KCM
Kingdon Capital Management
New York
|
-$5.49M |
| 3 |
Ikarian Capital
Dallas,
Texas
|
-$5M |
| 4 |
TLP
Tri Locum Partners
New York
|
-$4.66M |
| 5 |
Woodline Partners
San Francisco,
California
|
-$3.92M |
ACET Hedge Fund Activity: Q2 2022 in Review
101 of the 5,963 institutional investors tracked by Wall St. Rank reported a position in Adicet Bio (ACET) for Q2 2022, worth a combined $556M — down 16% from $660M a quarter earlier.
Buyers outnumbered sellers: 32 funds opened new ACET positions and 15 closed out — a net gain of 17 holders — while 35 added to existing stakes and 14 trimmed.
The largest buyer was Morgan Stanley, adding an estimated $22.2M. The largest seller was Avidity Partners Management, exiting entirely with an estimated $62.3M sold.
- 101 institutional investors held Adicet Bio (ACET) as of Q2 2022, up from 87 in Q1 2022.
- Funds reported $556M of Adicet Bio stock for Q2 2022, down 16% quarter-over-quarter.
- 32 funds opened new Adicet Bio positions in Q2 2022 and 15 closed out, a net change of +17 holders.
- The largest Adicet Bio buyer in Q2 2022 was Morgan Stanley, an estimated $22.2M added.
- The largest Adicet Bio seller in Q2 2022 was Avidity Partners Management, an estimated $62.3M sold.
Based on aggregated 13F filings for Q2 2022.